Search This Blog

Tuesday, December 19, 2023

Innate Pharma Licenses 4th Natural Killer Cell Engager in Oncology to Sanofi

 

  • Sanofi to exercise one option to license a new ANKET® program from Innate; After a research collaboration period, Sanofi will be responsible for all development, manufacturing and commercialization of the program
  • Innate to receive €15m as option exercise payment
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)